FDA Drug Review News
FDA Approves Zurampic® (lesinurad) for Adjunctive Treatment of Gout
In December 2015, Zurampic was FDA-approved to be used in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia in patients with gout who had not achieved target serum uric acid levels. Zurampic reduces serum uric acid levels by inhibiting the function of transporter proteins (URAT1 and OAT4), which are involved in uric acid reabsorption in the kidneys.
The recommended daily dose of Zurampic is 200 mg. It should be taken with food and always be co-administered with a xanthine oxidase inhibitor, such as allopurinol or Uloric® (febuxostat). The use of Zurampic is not recommended for patients taking less than 300 mg of allopurinol daily. Zurampic contains a Black Box Warning that states “acute renal failure has occurred with Zurampic, especially when given as monotherapy.”